Brisbane, Australia, 28 June 2018 — ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, today provided an update on its Australian paediatric clinical study, Breathe Easy. The Breathe Easy study is evaluating the efficacy of ResApp’s smartphone application for the diagnosis of childhood acute respiratory disease using cough sounds. As of 27 June, 603 paediatric patients have been recruited in the double-blind, prospective study. Target numbers of patients for lower respiratory tract disease, lower respiratory tract infection, asthma/reactive airway disease and bronchiolitis have been exceeded. Recruitment will continue in July to increase the number of patients with pneumonia, croup and upper respiratory tract infection to target levels.
At the completion of recruitment and adjudication, an independent statistical analysis of the un-blinded study data will be performed by Curtin University health researchers.
“We are seeing strong recruitment at our Australian hospital sites with the beginning of winter and are now close to achieving full enrolment,” said Tony Keating, CEO and Managing Director of ResApp. “It is important that we recruit the required numbers of patients for each disease to ensure that we achieve statistical significance before we un-blind and analyse the dataset. These results are pivotal for the company as they will provide clinical data to support a CE mark submission which would open up access to the large European healthcare market.”
ResApp also advises that recruitment in its Australian double-blind, prospective adult study is progressing well with 567 adults enrolled as of 27 June.
About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease. ResApp’s machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional hardware. Clinical studies underway at leading hospitals in the United States and Australia have demonstrated accurate diagnosis of pneumonia, asthma/reactive airway disease, bronchiolitis, croup, chronic obstructive pulmonary disease and upper respiratory tract infections. ResApp has also obtained excellent results for screening of obstructive sleep apnoea in a proof-of-concept clinical study. Potential customers of ResApp’s products include healthcare providers in telehealth, emergency department, urgent care and primary care settings as well as humanitarian organisations in the developing world.
For more information on ResApp, visit www.resapphealth.com.au
ResApp Health Limited
ABN 51 094 468 318
Level 12, 100 Creek St, Brisbane, QLD 4000
© 2021 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257, South Korean Patent No. 1020812410000 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries. ResAppDx is not available for sale in the United States.